NRAS was selected for further study since it was the only miR-1304-5p target identified in our study to negatively associate with NB patient survival (albeit across all NB genotypes rather than specific to ALK-aberrant NB) and ALK TKI resistance in in vivo models33,34. This evidence concerns the gene ALK and neuroblastoma.